Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Registered Dietitians - A Cost Effective Investment In Health For Canadians
Dietitians of Canada (DC) released a report today describing the integral role played by registered dietitians, as members of multi-disciplinary teams that contribute to promoting and supporting health among Canadians. The Role of Registered Dietitians in Primary Health Care: Moving Forward - A National Perspective presents evidence for the cost-effectiveness of nutrition services in the prevention and treatment of chronic conditions such as diabetes, hypertension, cancer and heart disease.
generic viagra online
Study Links Depressive Mood, Racial Disparities In Preterm Birth
Women who have depression symptoms prior to becoming pregnant are at an increased risk for having preterm births, with the risk twice as high for black women as for white women, according to a study in the Journal of Women"s Health, Reuters reports. For the study, Amelia Gavin of the University of Washington and colleagues examined the links between race, preterm birth and pre-pregnancy depressive mood among 555 women. The study used data collected from 1990-1996 as part of a larger, long-term investigation of heart disease risk.Researchers determined that 18.1% of the 249 black women in the study gave birth prior to 37 weeks" gestation, compared with 8.5% of the 306 white women in the study. The study also found that 9.4% of black women had pre-pregnancy symptoms of depressive mood, compared with 7.2% of white women. After researchers accounted for other factors associated with preterm birth, such as body weight and sociodemographic characteristics, black women"s risk remained more than twice that of white women.Gavin said, "The black-white disparity in preterm birth may be in part a consequence of different exposures to depressive mood prior to pregnancy." She said, "Reproductive outcomes must be viewed in light of women"s health over the entire life-course, as well as during pregnancy," adding that the study"s results suggest that "the experience of cumulative health disadvantages or "weathering"" might play a role in increased risk for preterm birth (Hendry, Reuters, 6/25).
News of the day
Mri Data Showing Tysabri® Promoted Remyelination Presented At The 61st Annual Meeting Of The American Academy Of Neurology
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced results of a study demonstrating that TYSABRI® (natalizumab) promoted regeneration and stabilization of damage done to the myelin sheath, as measured by advanced MRI technology. Damage to the myelin sheath causes the symptoms of multiple sclerosis (MS). Additional posters will also be presented during the Congress highlighting the ability of TYSABRI, in some patients, to improve physical function and patient reported outcomes on cognition, quality of life, and fatigue. TYSABRI is the first approved MS therapy with reported data suggesting that some of the signs of disease progression can be stopped. The strong efficacy profile demonstrated in clinical trials is enhanced further from these data and may help redefine success in MS.
Endocrinology

Analysis Of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects Of Sucrose-Formulated Recombinant Factor VIII

New data pooled from four large, "real world" post-marketing surveillance studies showed that sucrose-formulated recombinant factor VIII (rFVIII-FS) reduced bleeding and provided data regarding adverse events in more than 950 patients with mild-to-severe hemophilia A. Additionally, rates of inhibitor formation were reported in both previously treated and previously untreated patients. The data were presented at the XXII Congress of the International Society on Thrombosis and Haemostasis (ISTH).(1)(2) In this analysis, the investigators judged rFVIII-FS hemostasis to be "good" or "very good" in 98.9 percent of patients. Serious adverse drug reactions were seen in 1.1 percent of patients and new (de novo) inhibitors were observed in 0.8 percent of patients. "In a "real world" setting, these data reflect some of the extensive global clinical experience with rFVIII-FS," said Georg Lemm, M.D., Ph.D., vice president, Global Clinical Development, and head, Hematology Group, Bayer Schering Pharma. "It is particularly noteworthy that a low rate of inhibitor formation was observed in this analysis of data pooled from post-marketing surveillance studies. Inhibitor formation is a significant challenge for both clinicians and their patients, and its treatment is costly and requires significant time to overcome." Open label study investigating the efficacy of prophylactic versus on-demand rFVIII-FS treatment In another presentation, (3) data from an open label clinical study that enrolled 20 adult men with severe hemophilia A (with and without target joints) demonstrated that patients who were changed from on-demand to prophylactic (preventive) infusions of rFVIII-FS had significantly reduced median joint bleeds per 6-month treatment period (zero events versus 15.0 events, respectively; PAbout Hemophilia A Hemophilia A, also known as factor VIII deficiency or classic hemophilia, is largely an inherited bleeding disorder in which one of the proteins needed to form blood clots in the body is missing or reduced. Hemophilia A is the most common type of hemophilia and is characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. Approximately 400,000 people around the world have hemophilia A. About Bayer HealthCare Pharmaceuticals Inc. Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals unit of Bayer HealthCare LLC, a subsidiary of Bayer Corporation. One of the world"s leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the U.S., Bayer HealthCare Pharmaceuticals comprises the following business units: Diagnostic Imaging, General Medicine, Specialty Medicine and Women"s Healthcare. The company"s aim is to provide products that will improve human health worldwide by diagnosing, preventing and treating diseases. Forward-looking statements This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our annual and interim reports filed with the Frankfurt Stock Exchange. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. References (1) Fukutake K, et al. Post-marketing experience with sucrose-formulated recombinant factor VIII in patients with hemophilia A. Poster no. PP-MO-577; XXII Congress of the International Society on Thrombosis and Haemostasis. (2) Fukutake K, et al. Inhibitor formation with sucrose-formulated recombinant factor VIII in patients with hemophilia A: Results from post-marketing surveillance studies. Poster no. PP-WE-579; XXII Congress of the International Society on Thrombosis and Haemostasis. (3) Collins P, et al. Efficacy of secondary prophylactic versus on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A with and without target joints. Poster no. PP-TH-584; XXII Congress of the International Society on Thrombosis and Haemostasis. Bayer HealthCare


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009